Riding GLP-1 wave, Novo Nordisk lays out $560M to boost drug production in China

[cafead]

via This year marks Novo Nordisk’s 30th anniversary in China, and it could also be the year the company's red-hot weight loss injection Wegovy (semaglutide) wins approval in the populous East Asian nation that’s increasingly grappling with diseases such as obesity and diabetes.

article source